TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11171733
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered IV daily for up to 5 days
Study: 9665023
Drug: 5% solution
Normalized name: Introl 75% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% solution of glucose (Control)
Study: 31994271
Drug: TPF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF chemotherapy and PI3K-AKT-mTOR inhibitors
Study: 25784079
Drug: Daily meditation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily meditation for six weeks (treatment group)
Study: 21619828
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg simvastatin, taken in evening for 4 months
Study: 16753449
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline 10 ml) biweekly for 12 weeks
Study: 9663366
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR 150 mg/d (150 mg QD)
Study: 9663366
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR 300 mg/d (150 mg BID)
Study: 3046791
Drug: darodipine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darodipine 100 mg twice a day
Study: 3046791
Drug: darodipine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: darodipine 150 mg twice a day
Study: 29611518
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of oxaliplatin-containing chemotherapy
Study: 29611518
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of oxaliplatin-containing chemotherapy
Study: 25843292
Drug: Ag-DC-CIK immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ag-DC-CIK immunotherapy
Study: 25843292
Drug: CIK treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIK treatment
Study: 25843292
Drug: Ag-DC-CIK treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ag-DC-CIK treatment
Study: 21865087
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine (Cervarix, GlaxoSmithKline)
Study: 18545693
Drug: L-arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine infusion
Study: 15262119
Drug: Intraperitoneal IL-2
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal IL-2 therapy
Study: 2192383
Drug: cognitive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: cognitive and behaviour therapy
Study: 25832687
Drug: Concurrent chemo-radiation
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemo-radiation alone (control)
Study: 19654536
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir administered during the first 6 months after penetrating keratoplasty
Study: 15536141
Drug: Intraperitoneal cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal cefazolin and ceftazidime (15 mg/kg rounded to nearest 100 mg)
Study: 15536141
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic (Phase I)
Study: 8261298
Drug: Urethral plug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urethral plug treatment
Study: 3899047
Drug: Monoamine oxidase
Normalized name: Monoamine oxidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoamine oxidase inhibitors (MAOIs) - clorgyline or tranylcypromine sulfate
Study: 24298907
Drug: Two-drug regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug regimen (clarithromycin and ethambutol)
Study: 22116196
Drug: Allopurinol (100‐300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (100‐300 mg/day)
Study: 17440125
Drug: Traditional weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Traditional weekly sessions
Study: 16138585
Drug: Huorongbushen 48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huorongbushen 48 g daily for 3 months
Study: 23609398
Drug: olanzapine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: olanzapine (10 mg)
Study: 12503835
Drug: thioridazine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: thioridazine (50 mg)
Study: 1671890
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (antibacterial agents withdrawn)
Study: 1671890
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of antibacterial therapy (without candida overgrowth)
Study: 6186329
Drug: Intravenous atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atenolol followed by oral atenolol (5 mg IV, then 50 mg oral, 50 mg oral 12 hours later, then 100 mg daily for 10 days)
Study: 6105436
Drug: Intravenous atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atenolol
Study: 10092302
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg urease + 5 microg heat-labile enterotoxin (LT)
Study: 10092302
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg urease + 5 microg heat-labile enterotoxin (LT)
Study: 10092302
Drug: Urease (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urease (any dose)
Study: 2538050
Drug: 10 or
Normalized name: K-10 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 or 15 g of soy polysaccharide fiber
Study: 2538050
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of soy polysaccharide fiber
Study: 140827
Drug: Tofranil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofranil (25 mg three times a day for four weeks)
Study: 28585859
Drug: Patiromer 25.2
Normalized name: patiromer 25.2 GM Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer 25.2 g coadministered with levothyroxine
Study: 28585859
Drug: Patiromer 25.2
Normalized name: patiromer 25.2 GM Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer 25.2 g coadministered with metformin
Study: 28585859
Drug: Patiromer 25.2
Normalized name: patiromer 25.2 GM Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer 25.2 g coadministered with ciprofloxacin
Study: 28585859
Drug: Patiromer 25.2
Normalized name: patiromer 25.2 GM Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer 25.2 g coadministered with various drugs
Study: 28585859
Drug: Patiromer 25.2
Normalized name: patiromer 25.2 GM Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer 25.2 g coadministered with ciprofloxacin, levothyroxine, and metformin
Study: 25749297
Drug: Darapladib 160
Normalized name: Darapladib
DrugBank: Darapladib (DB06311)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darapladib 160 mg once daily for 3 months
Study: 23807837
Drug: Multimodal microemulsion
Normalized name: cyclosporine microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal microemulsion (formulation A)
Study: 23807837
Drug: Minoxidil alone
Normalized name: Minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minoxidil alone (formulation B)
Study: 23807837
Drug: Placebo (formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (formulation C)
Study: 12584283
Drug: Sevelamer hydrochloride
Normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer hydrochloride (initial dose: 2.4 g/day, increased to 4.4 g/day)
Study: 12584283
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (4.8 g/day)
Study: 11357004
Drug: High-dose GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GH treatment (0.3 IU/kg) interrupted
Study: 1589558
Drug: Ethanol 0.9
Normalized name: ethanol 0.9 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.9 g/kg body weight
Study: 2895705
Drug: Flunitrazepam 1
Normalized name: flunitrazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 1 mg
Study: 11519634
Drug: Diazepam 20
Normalized name: diazePAM 20 mg rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 20 mg
Study: 2223425
Drug: Flunitrazepam 2
Normalized name: flunitrazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 2 mg
Study: 1589558
Drug: Flunitrazepam 1
Normalized name: flunitrazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 1 mg and Diazepam 20 mg
Study: 1589558
Drug: Flunitrazepam treatments
Normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam treatments
Study: 23540189
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no rHuEPO, received oral iron and folic acid from day 14)
Study: 7657846
Drug: Flecainide 200
Normalized name: flecainide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide 200 mg/day
Study: 23466591
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate 10 g daily
Study: 12091294
Drug: Moderately early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately early postnatal dexamethasone treatment (4.75 mg/kg over 14 days from the 10th day of life)
Study: 7854168
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) at a dose of 0.25 to 0.5 U/kg/wk, administered subcutaneously once a day in the evening.
Study: 7854168
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) treatment.
Study: 22108473
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Pycnogenol® and compression stockings (group 3)
Study: 22108473
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Pycnogenol® and compression stockings
Study: 15588339
Drug: Emtricitabine (FTC)
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Emtricitabine (FTC) 200 mg qd
Study: 15588339
Drug: Emtricitabine (FTC)
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Emtricitabine (FTC) 200 mg qd in HIV-infected patients
Study: 15588339
Drug: Emtricitabine (FTC)
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Emtricitabine (FTC) 200 mg/day
Study: 11907840
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate foam (BMV foam), 0.12%, applied twice daily for 12 weeks
Study: 11907840
Drug: Placebo foam,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo foam, applied twice daily for 12 weeks
Study: 9735502
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with protease inhibitors (PI)
Study: 3365458
Drug: MK-212 20
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-212 20 mg
Study: 3365458
Drug: MK-212 40
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-212 40 mg
Study: 3365458
Drug: MK-212 (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-212 (10, 20, 40 mg)
Study: 21210338
Drug: Zolpidem (0.14-0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (0.14-0.2 mg/kg daily for 4 days)
Study: 21210338
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for 4 days)
Study: 2566251
Drug: Atracurium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.5 mg kg‐1
Study: 7999489
Drug: Mivacurium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 0.15 mg kg‐1
Study: 9861140
Drug: Mivacurium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 0.2 mg kg‐1
Study: 28619
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg/day)
Study: 30081859
Drug: Baseline (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline (no treatment)
Study: 95729
Drug: Intranasal luteinising-hormone
Normalized name: Luteinising hormone
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal luteinising-hormone releasing hormone (L.H.R.H.) administered in six doses daily (1.2 mg/day) for four weeks
Study: 10788675
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light treatment
Study: 11962682
Drug: Chronomodulated chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronomodulated chemotherapy (B)
Study: 2246042
Drug: Prenatal iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal iron supplements (oral or parenteral)
Study: 2246042
Drug: Parenteral iron
Normalized name: Iron, parenteral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral iron
Study: 556551
Drug: Cyclic polychemotherapy
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic polychemotherapy (cyclophosphamide, mercaptopurine, prednisolone, dipyridamol, heparin)
Study: 556551
Drug: Continuous two-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous two-drug regimen (mercaptopurine + prednisolone)
Study: 25881677
Drug: Sumatriptan/Naproxen Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan/Naproxen Sodium (S/NS) 85/500 mg
Study: 14982688
Drug: Bupropion hydrochloride
Normalized name: Bupropion Hydrochloride
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion hydrochloride sustained-release (Zyban)
Study: 10910479
Drug: Rocuronium 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.4 mg/kg
Study: 9416722
Drug: Rocuronium 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.8 mg/kg
Study: 17312208
Drug: Rocuronium 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 1.2 mg/kg
Study: 2688507
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rHuEpo) therapy
Study: 23768736
Drug: Nebulizer with
Normalized name: AeroNeb Go Nebulizer with Cable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulizer with Combivent (2.5 mg salbutamol and 250 mcg ipratropium per mL)
Study: 16384759
Drug: Combination clindamycin
Normalized name: clindamycin, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination clindamycin (1%) and tretinoin (0.025%) hydrogel
Study: 8360134
Drug: Oral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluconazole (50 mg/day as a single dose)
Study: 8824962
Drug: Oral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluconazole
Study: 8360134
Drug: Oral polyenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral polyenes
Study: 3090906
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NTG) at doses up to 40 micrograms X kg‐1 X min‐1
Study: 3090906
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (SNP) at doses of 6‐8 micrograms X kg‐1 X min‐1
Study: 26945711
Drug: Atazanavir/ritonavir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir monotherapy
Study: 26945711
Drug: Atazanavir/ritonavir triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir triple therapy
Study: 25679130
Drug: Slow-release oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release oral morphine (SROM)
Study: 21633047
Drug: Standard-dose XT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose XT (capecitabine 1250 mg/m² twice daily, days 1-14; docetaxel 75 mg/m², day 1 every 3 weeks)
Study: 21633047
Drug: Low-dose XT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose XT (capecitabine 825 mg/m² twice daily, days 1-14; docetaxel as above)
Study: 12867219
Drug: L-carnitine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (1 tablet BID)
Study: 8166033
Drug: Di‐Gel Lemon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Di‐Gel Lemon Orange
Study: 24135218
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of angiotensin‐converting enzyme inhibitor and angiotensin receptor blocker
Study: 24135218
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with either angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker
Study: 21438793
Drug: fenofibric acid
Normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenofibric acid + moderate-dose statin
Study: 21438793
Drug: fenofibric acid
Normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenofibric acid + low-dose statin
Study: 21438793
Drug: fenofibric acid
Normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenofibric acid + low- and moderate-dose statin
Study: 31577697
Drug: YGJT (3g
Approvals — FDA: no, EMA: no, PMDA: no
Description: YGJT (3g twice a day for 4 weeks) + nutrition counseling
Study: 23442225
Drug: VA (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: VA (2000 IU daily retinol)
Study: 23442225
Drug: VD (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: VD (400 IU daily cholecalciferol)
Study: 23442225
Drug: VAD (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAD (2000 IU daily retinol plus 400 IU cholecalciferol)
Study: 21466079
Drug: Video condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video condition (participants who watched a video of their precompetition preparation)
Study: 8410923
Drug: Lisinopril vs
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril vs Placebo
Study: 3776903
Drug: Intravenous 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous 5-FU
Study: 28970291
Drug: EBL plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBL plus propranolol (EBL+drug)
Study: 20573348
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus (40 mg vaginal application once weekly for 6 months)
Study: 15845315
Drug: Overall (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall (all treatments)
Study: 9478315
Drug: 17-alpha-hydroxyprogesterone caproate
Normalized name: 17-alpha-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-alpha-hydroxyprogesterone caproate (341 mg once a week)
Study: 9478315
Drug: Natural Progesterone
Normalized name: NATURAL PROGESTERONE CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural Progesterone (50 mg/day)
Study: 29665062
Drug: 3% JTE-052
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% JTE-052 ointment
Study: 24767638
Drug: PCEA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA with 1 mg/mL ropivacaine and 2 μg/mL fentanyl (Group A)
Study: 24767638
Drug: PCEA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA with 0.8 mg/mL bupivacaine (Group B)
Study: 24767638
Drug: CEI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEI with 1 mg/mL ropivacaine (Group C)
Study: 24767638
Drug: CEI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEI with 0.8 mg/mL bupivacaine (Group D)
Study: 22364262
Drug: Candesartan (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (8 mg/day) with ursodeoxycholic acid (UDCA) (600 mg/day)
Study: 20698351
Drug: Topical difluoromethylornithine
Normalized name: α-difluoromethylornithine
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical difluoromethylornithine (DFMO)
Study: 20698351
Drug: Topical Triamcinolone
Normalized name: triamcinolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Triamcinolone
Study: 20698351
Drug: Topical difluoromethylornithine
Normalized name: α-difluoromethylornithine
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical difluoromethylornithine (DFMO) + Triamcinolone
Study: 17442512
Drug: Kangxin capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangxin capsule
Study: 11829697
Drug: 0.625 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/d of conjugated equine estrogen plus 2.5 mg/d of medroxyprogesterone acetate (n = 1380)
Study: 11829697
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (hormone therapy and placebo)
Study: 10510146
Drug: L‐NMMA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA (4 mg kg‐1 bolus, with 4 mg kg‐1 infusion)
Study: 8731849
Drug: 200mg vitamin
Normalized name: vitamin B6 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg vitamin C twice a day for 3 months
Study: 15560690
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for 3 months
Study: 11505744
Drug: Amlodipine (2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5-10 mg once daily)
Study: 6111965
Drug: Carbonated beverage
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbonated beverage with syrup of ipecac